NHS Eligibility Guide for Weight-Loss Medication

Weight-loss medications such as Wegovy (semaglutide) and Mounjaro (tirzepatide) are clinically approved treatments used to support weight loss in people living with obesity. In the UK, these medicines may be available through the NHS for a limited group of patients who meet strict eligibility criteria, or privately following a medical assessment.

This guide explains who may qualify for NHS-prescribed weight-loss medication, how access works, and how NHS eligibility compares with private treatment options.

If you are still exploring available treatment options, eligibility criteria, and how to start a consultation, our weight loss injections page explains NHS eligibility at a high level and outlines the private treatment options available through Happy Pharmacy.

Can You Get Weight-Loss Medication on the NHS?

The NHS does not routinely prescribe weight-loss injections to everyone who is overweight. Access is limited to patients who meet strict clinical criteria and where obesity is having a significant impact on health. Eligibility is based on national NHS and NICE guidance and often requires referral into a specialist weight-management service [1][2].

NHS Eligibility Criteria for Weight-Loss Medication

To be considered for NHS-funded weight-loss medication, patients generally need to meet all of the following criteria.

✅ Body Mass Index (BMI)

• BMI of 35 or higher, or

• BMI of 30 or higher with at least one obesity-related health condition

✅ Obesity-Related Health Conditions

These may include:

• Type 2 diabetes

• High blood pressure (hypertension)

• High cholesterol

• Obstructive sleep apnoea

• Cardiovascular disease

✅ Previous Weight-Management Attempts

Patients are usually expected to have:

• Taken part in structured diet and lifestyle interventions, and

• Been unable to achieve or maintain sufficient weight loss through these measures alone [2].

Which Weight-Loss Medications Are Available on the NHS?

Wegovy (Semaglutide)

Wegovy is approved for use within specialist NHS weight-management services for patients who meet strict eligibility criteria. Clinical trial data shows that semaglutide can lead to significant and sustained weight loss when combined with dietary changes and increased physical activity [3].

Mounjaro (Tirzepatide)

Tirzepatide has demonstrated greater average weight-loss outcomes in clinical trials compared with earlier GLP-1 medicines. NHS access is expected to be prioritised for patients at the highest clinical risk, and availability may vary depending on local commissioning decisions [5].

How Do GLP-1 Weight-Loss Medicines Work?

GLP-1 receptor agonists work by mimicking a naturally occurring hormone involved in appetite and blood-sugar regulation. These medicines act on receptors in the brain and digestive system to reduce hunger, increase feelings of fullness, and slow digestion, which can help reduce calorie intake over time [4].

For a more detailed explanation of how GLP-1 weight-loss injections work, including expected results and who they are suitable for, see our GLP-1 weight loss injections complete guide.

How Long Does NHS Access Take?

Even when patients meet clinical eligibility criteria, access to NHS weight-loss medication can be delayed. Specialist services have limited capacity, and availability can vary between regions. As a result, some eligible patients experience long waiting times before starting treatment [6].

Eligibility for Private Weight-Loss Treatment

For patients who do not qualify for NHS treatment, or who prefer not to wait for NHS access, private prescribing may be an option following a clinical assessment.

Private weight-loss prescriptions are only issued when it is medically appropriate and after reviewing a patient’s health history, BMI, and suitability for treatment.

Private Mounjaro Eligibility

Mounjaro may be considered for private treatment if you meet the following criteria:

• BMI of 30 or higher, or 27 or higher with weight-related health conditions

• Not pregnant or breastfeeding

• Not currently taking another GLP-1 medication

• Not suitable for people with type 1 diabetes

• Often considered for patients with insulin resistance or increased metabolic risk

If you are considering private treatment and want to understand how quickly results may occur, our Mounjaro weight-loss timeline and results guide outlines what to expect over time with tirzepatide treatment.

Private Wegovy Eligibility

Wegovy may be suitable for private treatment if you meet the following criteria:

• BMI of 30 or higher, or 27 or higher with weight-related health conditions

• Able to follow a calorie-controlled diet and increase physical activity

• Not pregnant or breastfeeding

• Not currently taking another GLP-1 medication

NHS vs Private Weight-Loss Prescriptions

Important Safety Information

Weight-loss injections are prescription-only medicines and are not suitable for everyone. They must be used alongside lifestyle changes and under appropriate medical supervision. Always seek advice from a qualified healthcare professional before starting any weight-loss medication.